TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Health Literacy and Numeracy to Prevent Childhood Obesity
Brief Summary: In 2003, Surgeon General Richard Carmona suggested that low health literacy is "one of the largest contributors to our nation's epidemic of overweight and obesity." Over 26% of preschool children are now overweight or obese, and children who are overweight by age 24 months are five times as likely as non-overweight children to become overweight adolescents. The aim of the study is to assess the efficacy of a low-literacy/numeracy-oriented intervention aimed at teaching pediatric resident physicians to promote healthy family lifestyles and prevent overweight among young children (age 0-2) and their families in under-resourced communities.


Options:
A: Arm Label: Active Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Injury Prevention Arm | Arm Label: Health Communication and Obesity Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Health Communication and Obesity Prevention; Assigned to Arm(s): Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Injury Prevention Arm; Assigned to Arm(s): Active Control Arm
B: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Lifestyle counseling; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: Eating and physical activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Eating and physical activity counseling | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Eating and physical activity counseling; Assigned to Arm(s): Eating and physical activity counseling
D: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Wait-listed control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Health Literacy and Numeracy to Prevent Childhood Obesity
Brief Summary: In 2003, Surgeon General Richard Carmona suggested that low health literacy is "one of the largest contributors to our nation's epidemic of overweight and obesity." Over 26% of preschool children are now overweight or obese, and children who are overweight by age 24 months are five times as likely as non-overweight children to become overweight adolescents. The aim of the study is to assess the efficacy of a low-literacy/numeracy-oriented intervention aimed at teaching pediatric resident physicians to promote healthy family lifestyles and prevent overweight among young children (age 0-2) and their families in under-resourced communities.


Options:
A: Arm Label: Control; Type: OTHER; Interventions: Other: Control | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: BALANCE; Type: EXPERIMENTAL; Interventions: Behavioral: BALANCE | Intervention Type: BEHAVIORAL; Name: BALANCE; Assigned to Arm(s): BALANCE
C: Arm Label: dietary intervention 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: lemonade with sugar | Arm Label: dietary intervention 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: lemonade low in sugar | Intervention Type: DIETARY_SUPPLEMENT; Name: lemonade with sugar; Assigned to Arm(s): dietary intervention 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: lemonade low in sugar; Assigned to Arm(s): dietary intervention 2
D: Arm Label: Active Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Injury Prevention Arm | Arm Label: Health Communication and Obesity Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Health Communication and Obesity Prevention; Assigned to Arm(s): Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Injury Prevention Arm; Assigned to Arm(s): Active Control Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Health Literacy and Numeracy to Prevent Childhood Obesity
Brief Summary: In 2003, Surgeon General Richard Carmona suggested that low health literacy is "one of the largest contributors to our nation's epidemic of overweight and obesity." Over 26% of preschool children are now overweight or obese, and children who are overweight by age 24 months are five times as likely as non-overweight children to become overweight adolescents. The aim of the study is to assess the efficacy of a low-literacy/numeracy-oriented intervention aimed at teaching pediatric resident physicians to promote healthy family lifestyles and prevent overweight among young children (age 0-2) and their families in under-resourced communities.


Options:
A: Intervention Type: BEHAVIORAL; Name: Targeted parental instruction for positive lifestyle change with follow-up calls.; Assigned to Arm(s): N/A
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Other: Childhood Obesity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Childhood Obesity; Assigned to Arm(s): Treatment
C: Arm Label: Active Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Injury Prevention Arm | Arm Label: Health Communication and Obesity Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Health Communication and Obesity Prevention; Assigned to Arm(s): Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Injury Prevention Arm; Assigned to Arm(s): Active Control Arm
D: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women
Brief Summary: Primary objective: To assess the efficacy of adding raloxifene as an adjunct to antipsychotic treatment to improve negative symptoms of schizophrenia in postmenopausal women.

This is a double-blind, randomized, placebo-controlled study of raloxifene as adjuvant treatment to antipsychotic treatment. Treatment period of 12 weeks.

The primary result obtained is that women treated with 60 mg of raloxifene compared to those treated with a placebo show greater improvement in psychotic symptoms. The investigators also found improved response in some aspects of social functioning and neuropsychological functioning.


Options:
A: Arm Label: Vagifem; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vagifem, Other: Placebo gel | Arm Label: Replens; Type: ACTIVE_COMPARATOR; Interventions: Device: Replens, Other: Placebo tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet, Other: Placebo gel | Intervention Type: DRUG; Name: Vagifem; Assigned to Arm(s): Vagifem | Intervention Type: DEVICE; Name: Replens; Assigned to Arm(s): Replens | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo, Replens | Intervention Type: OTHER; Name: Placebo gel; Assigned to Arm(s): Placebo, Vagifem
B: Arm Label: sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: raloxifene | Arm Label: raloxifene hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: raloxifene | Intervention Type: DRUG; Name: raloxifene; Assigned to Arm(s): raloxifene hydrochloride, sugar pill
C: Arm Label: Ospemifene; Type: EXPERIMENTAL; Interventions: Drug: Ospemifene | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ospemifene; Assigned to Arm(s): Ospemifene | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 17-b-estradiol, Drug: 17-b-estradiol + medroxyprogeterone acetate, Drug: 17-b-estradiol hemihydrate, Drug: placebo pill + gel | Intervention Type: DRUG; Name: 17-b-estradiol; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol + medroxyprogeterone acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 17-b-estradiol hemihydrate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: placebo pill + gel; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer
Brief Summary: This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with HER2-positive advanced gastric cancer. Trastuzumab (Herceptin) will be administered as intravenous infusion of 6 mg/kg (loading dose 8 mg/kg) every 3 weeks. The chemotherapy consists of a combination of 6 cycles of fluorouracil (800 mg/m2/day intravenous infusion every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks), or capecitabine (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks). Treatment with trastuzumab (Herceptin) will continue until disease progression. The target sample size is 300-600 patients.


Options:
A: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin
B: Arm Label: Olaparib+ paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Paclitaxel | Arm Label: Placebo+paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib+ paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Olaparib+ paclitaxel, Placebo+paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+paclitaxel
C: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
D: Arm Label: TAS-102+BSC; Type: EXPERIMENTAL; Interventions: Drug: TAS-102 | Arm Label: Placebo+BSC; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: TAS-102; Assigned to Arm(s): TAS-102+BSC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+BSC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study
Brief Summary: Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms and signs of peripheral arterial disease over placebo after four weeks of therapy. As well this study will examine whether improvements in blood vessel function can be observed. Finally, we will measure blood vessel function and stem cell levels in order to determine whether they can help to predict whether patients wither peripheral arterial disease will suffer further cardiovascular complications.


Options:
A: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A: GM-CSF + supervised treadmill exercise therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Treadmill Exercise Therapy, Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: B: GM-CSF + attention control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions (Control), Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: C: placebo + supervised exercise therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Treadmill Exercise Therapy | Arm Label: D: placebo + attention control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health education sessions (Control) | Intervention Type: BEHAVIORAL; Name: Supervised Treadmill Exercise Therapy; Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, C: placebo + supervised exercise therapy | Intervention Type: OTHER; Name: Health education sessions (Control); Assigned to Arm(s): B: GM-CSF + attention control group, D: placebo + attention control group | Intervention Type: DRUG; Name: granulocyte macrophage colony stimulating factor (GM-CSF); Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, B: GM-CSF + attention control group
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: MESENDO; Type: EXPERIMENTAL; Interventions: Biological: MESENDO | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MESENDO; Assigned to Arm(s): MESENDO | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study
Brief Summary: Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms and signs of peripheral arterial disease over placebo after four weeks of therapy. As well this study will examine whether improvements in blood vessel function can be observed. Finally, we will measure blood vessel function and stem cell levels in order to determine whether they can help to predict whether patients wither peripheral arterial disease will suffer further cardiovascular complications.


Options:
A: Arm Label: 4times injection; Type: EXPERIMENTAL; Interventions: Biological: 4times injection | Arm Label: one injection; Type: EXPERIMENTAL; Interventions: Biological: stem cell transplantation | Intervention Type: BIOLOGICAL; Name: 4times injection; Assigned to Arm(s): 4times injection | Intervention Type: BIOLOGICAL; Name: stem cell transplantation; Assigned to Arm(s): one injection
B: Intervention Type: GENETIC; Name: Autologous peripheral blood CD34 positive cell therapy; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: cell therapy; Assigned to Arm(s): N/A
D: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study
Brief Summary: Peripheral arterial disease is a common condition in older adults involving poor arterial circulation in the legs leading to leg pain and debility. The body's own circulating blood vessel stem cells may help to improve circulation. This study will test whether treatment with the drug granulocyte macrophage colony stimulating factor (GM-CSF) will improve symptoms and signs of peripheral arterial disease over placebo after four weeks of therapy. As well this study will examine whether improvements in blood vessel function can be observed. Finally, we will measure blood vessel function and stem cell levels in order to determine whether they can help to predict whether patients wither peripheral arterial disease will suffer further cardiovascular complications.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
B: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: autologous purified CD34+ cell; Type: EXPERIMENTAL; Interventions: Other: autologous purified CD34+ cells | Arm Label: autologous PB-MNC; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous peripheral blood mononuclear cells | Intervention Type: OTHER; Name: autologous purified CD34+ cells; Assigned to Arm(s): autologous purified CD34+ cell | Intervention Type: OTHER; Name: autologous peripheral blood mononuclear cells; Assigned to Arm(s): autologous PB-MNC
D: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: US Pilot Safety and Feasibility Study of Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction in Patients With Heterogeneous Emphysema With Upper Lobe Predominance
Brief Summary: To assess the safety and efficacy of BTVA for the treatment of patients with heterogeneous upper lobe emphysema.


Options:
A: Arm Label: BTVA; Type: EXPERIMENTAL; Interventions: Device: BTVA System | Intervention Type: DEVICE; Name: BTVA System; Assigned to Arm(s): BTVA
B: Intervention Type: DEVICE; Name: AeriSeal System; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: AeriSeal System; Assigned to Arm(s): N/A
D: Arm Label: bilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Arm Label: unilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): unilateral | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): bilateral

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability
Brief Summary: This multi-center (6 sites: Helsinki, Kuopio, Oulu, Seinäjoki, Turku, Vantaa) intervention study aims to prevent cognitive impairment, dementia and disability in 60-77 year old persons at an increased dementia risk. The 2-year multi-domain life-style intervention includes nutritional guidance, exercise, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors. The primary outcome is cognitive impairment measured by a sensitive Neuropsychological Test Battery (NTB), and Stroop and Trail Making tests to capture early cognitive impairment typical for both Alzheimer's disease and vascular dementia. We hypothesize that the multi-domain intervention will reduce cognitive impairment in the study group compared to the control group during the initial 2-year intervention period and reduce dementia incidence after the extended follow-up (until at least 300 participants have developed dementia).


Options:
A: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling
B: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3, Behavioral: multi-domain intervention | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: multi-domain intervention, Drug: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: multi-domain intervention; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4
D: Intervention Type: DRUG; Name: Naproxen Sodium (Aleve); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A

Answer: A